ADRU - Invesco BLDRS Europe Select ADR Index Fund

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.95
+0.15 (+0.76%)
As of 1:23PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close19.80
Open19.95
Bid19.91 x 1000
Ask19.95 x 800
Day's Range19.95 - 19.95
52 Week Range18.35 - 22.24
Volume4,200
Avg. Volume746
Net Assets11.42M
NAV19.86
PE Ratio (TTM)N/A
Yield3.77%
YTD Return6.27%
Beta (3Y Monthly)0.98
Expense Ratio (net)0.30%
Inception Date2002-11-13
Trade prices are not sourced from all markets
  • Recommendations for GlaxoSmithKline on October 29
    Market Realist

    Recommendations for GlaxoSmithKline on October 29

    Wall Street analysts are estimating that GlaxoSmithKline will report revenues of ~8.02 billion pounds for the third quarter of 2018. GlaxoSmithKline stock has increased ~8.5% over the last 12 months and ~10.8% year-to-date. Analyst recommendations show a 12-month target price of $44.31 per share compared to its last price of $39.32 on October 26.

  • What Analysts Recommend for Novartis after Q3 Earnings
    Market Realist

    What Analysts Recommend for Novartis after Q3 Earnings

    Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.

  • How Novartis’s Innovative Medicines Business Performed in Q3
    Market Realist

    How Novartis’s Innovative Medicines Business Performed in Q3

    Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.

  • A Closer Look at Novartis’s Innovative Medicines Segment
    Market Realist

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

  • Novartis ADR’s Performance and Revenue Estimates for Q3 2018
    Market Realist

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.

  • How GlaxoSmithKline’s Segments Performed
    Market Realist

    How GlaxoSmithKline’s Segments Performed

    GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.

  • Novartis to Divest Portions of Sandoz US to Aurobindo
    Market Realist

    Novartis to Divest Portions of Sandoz US to Aurobindo

    Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.

  • Novartis’s Sandoz in Q2 2018
    Market Realist

    Novartis’s Sandoz in Q2 2018

    Sandoz is Novartis’s (NVS) generics business and is a market leader in differentiated generics. Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.

  • Novartis’s SOLAR-1 Trial Met Primary Endpoint
    Market Realist

    Novartis’s SOLAR-1 Trial Met Primary Endpoint

    Novartis (NVS) announced on August 23 that its SOLAR-1 trial, a Phase 3 trial evaluating investigational drug BYL719 (alpelisib) in combination with fulvestrant, has met its primary endpoint.